This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
PCRXNegative Net Change USNAPositive Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.
NBIXPositive Net Change USNAPositive Net Change XENENegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
by Zacks Equity Research
KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.
SNYPositive Net Change GILDPositive Net Change CSTLNegative Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
by Zacks Equity Research
Denali posts narrower-than-expected Q4 loss as FDA extends review of tividenofusp alfa, with $966M cash backing pipeline advances and no Q4 revenues.
SNYPositive Net Change BIIBPositive Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
by Zacks Equity Research
VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.
ANIPNegative Net Change ALLOPositive Net Change CSTLNegative Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance
by Zacks Equity Research
ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.
ANIPNegative Net Change ADMAPositive Net Change ALLOPositive Net Change CSTLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.
CPRXNegative Net Change USNAPositive Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
After Golden Cross, CMS Energy (CMS)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
CMSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
by Zacks Equity Research
Acadia beats Q4 EPS estimates as Nuplazid and Daybue lift revenues 9%, but sales miss and EU setback cloud trofinetide outlook with 2026 sales at $1.22-$1.28 billion.
USNAPositive Net Change ACADNegative Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
by Zacks Equity Research
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
SNYPositive Net Change BMYPositive Net Change BAYRYNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals